A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsartan plus HCTZ for 34 weeks with or without respective measures

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To demonstrate that supportive measures improve drug adherence in patients with mild essential hypertension treated with valsartan 160 mg or valsartan 160 mg plus HCTZ 12.5 mg for 34 weeks. To assess adherence, data on compliance and persistence will be collected. For primary efficacy the daily proportion of patients taking one tablet of the prescribed hypertensive therapy between 07:00 and 11:00AM will be assessed using an electronic monitor (MEMS) and will be compared between randomized groups over the course of the study.

Critère d'inclusion

Patients with essential hypertension

Liens

euctr
ictrp

Kusajili – Centralise les essais cliniques mondiaux

A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsarta...